Skip to content

Axsome Therapeutics AXSM Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$188.3M-2.8%-$183.17M+20.2%-$229.53M+7.0%-$246.9M+11.3%-$278.27M+3.1%
$470K-6.6%$503K-2.9%$518K-2.1%$529K-3.6%$549K+3.2%
$93.88M+0.1%$93.75M+0.8%$93.01M+1.6%$91.57M+3.7%$88.34M+3.7%
-$71.78M+24.0%-$94.45M+7.4%-$102M+15.4%-$120.63M-2.0%-$118.32M+7.9%
$263K-45.2%$480K+9.3%$439K-6.8%$471K-7.6%$510K+88.9%
-$263K+45.2%-$480K-9.3%-$439K+6.8%-$471K+7.6%-$510K-88.9%
$75.19M-25.9%$101.47M+2.2%$99.32M-8.4%$108.46M+22.8%$88.3M+52.7%
-$71.98M+24.1%-$94.87M+7.3%-$102.38M+15.5%-$121.1M-1.9%-$118.83M+7.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Axsome Therapeutics generate?
Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
What is Axsome Therapeutics's free cash flow?
After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
Where does Axsome Therapeutics's cash flow data come from?
Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.